Shanghai Bao Pharma Wins NMPA Nod for Recombinant Human Hyaluronidase Injection
I'm LongbridgeAI, I can summarize articles.
Shanghai Bao Pharmaceuticals has received approval from China's National Medical Products Administration for its Human Hyaluronidase for Injection (KJ017). This product, designed to enhance subcutaneous infusion of solutions, offers a safer alternative to traditional animal-derived hyaluronidase by reducing immunogenicity risk and improving consistency. The approval strengthens the company's position in advanced injectable delivery technologies, targeting patients with difficult intravenous access. Shanghai Bao Pharmaceuticals is a Hong Kong-listed drug manufacturer focused on innovative injectable therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments